Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.

Hiatt WR, Kaul S, Smith RJ.

N Engl J Med. 2013 Oct 3;369(14):1285-7. doi: 10.1056/NEJMp1309610. Epub 2013 Sep 2. No abstract available.

2.

Rosiglitazone and cardiovascular risk.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jun 14;356(24):2522-4. Epub 2007 May 21. No abstract available.

3.

Rosiglitazone: what went wrong?

Cohen D.

BMJ. 2010 Sep 6;341:c4848. doi: 10.1136/bmj.c4848. No abstract available.

PMID:
20819889
4.

The record on rosiglitazone and the risk of myocardial infarction.

Psaty BM, Furberg CD.

N Engl J Med. 2007 Jul 5;357(1):67-9. Epub 2007 Jun 5. No abstract available.

5.

Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?

Freemantle N.

BMJ. 2010 Sep 6;341:c4812. doi: 10.1136/bmj.c4812. No abstract available.

PMID:
20819888
6.

Rosiglitazone and the FDA.

Joffe HV, Parks MH, Meyer RJ, Jenkins JK, Temple R.

N Engl J Med. 2007 Oct 25;357(17):1775-6; author reply 1777. Epub 2007 Aug 29. No abstract available.

7.

Rosiglitazone, marketing, and medical science.

Moynihan R.

BMJ. 2010 Apr 7;340:c1848. doi: 10.1136/bmj.c1848. No abstract available.

PMID:
20375091
8.

The Avandia debate: an unhappy conclusion.

Bloomgarden Z, Handelsman Y.

J Diabetes. 2010 Dec;2(4):221-2. doi: 10.1111/j.1753-0407.2010.00096.x. No abstract available.

9.

FDA committee urges tight restrictions on rosiglitazone.

Roehr B.

BMJ. 2010 Jul 16;341:c3862. doi: 10.1136/bmj.c3862. No abstract available.

PMID:
20639290
10.

Rosiglitazone: trials, tribulations and termination.

Krentz AJ.

Drugs. 2011 Jan 22;71(2):123-30. doi: 10.2165/11585300-000000000-00000. No abstract available.

PMID:
21275442
11.

Rosiglitazone and cardiovascular risk.

Mannucci E, Monami M, Marchionni N.

N Engl J Med. 2007 Aug 30;357(9):938; author reply 939-40. No abstract available.

PMID:
17806136
12.

Licensing drugs for diabetes.

Lehman R, Yudkin JS, Krumholz H.

BMJ. 2010 Sep 6;341:c4805. doi: 10.1136/bmj.c4805. No abstract available.

PMID:
20819887
13.

Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.

[No authors listed]

Harv Heart Lett. 2007 Aug;17(12):1-2. No abstract available.

PMID:
17717888
14.

Rosiglitazone and cardiovascular risk.

Bracken MB.

N Engl J Med. 2007 Aug 30;357(9):937-8; author reply 939-40. No abstract available.

15.

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Nissen SE, Wolski K.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207. Review.

PMID:
20656674
16.

Rosiglitazone--continued uncertainty about safety.

Drazen JM, Morrissey S, Curfman GD.

N Engl J Med. 2007 Jul 5;357(1):63-4. Epub 2007 Jun 5. No abstract available.

17.

Rosiglitazone and cardiovascular risk.

Diamond GA, Kaul S.

N Engl J Med. 2007 Aug 30;357(9):938-9; author reply 939-40. No abstract available.

PMID:
17806135
18.

Rosiglitazone: a thunderstorm from scarce and fragile data.

Mulrow CD, Cornell J, Localio AR.

Ann Intern Med. 2007 Oct 16;147(8):585-7. No abstract available.

PMID:
17938398
19.

Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.

Woodcock J, Sharfstein JM, Hamburg M.

N Engl J Med. 2010 Oct 14;363(16):1489-91. doi: 10.1056/NEJMp1010788. Epub 2010 Sep 23. No abstract available.

20.

The Yin and the Yang of CV risks in patients with diabetes.

Dangi-Garimella S.

Am J Manag Care. 2014 May;20(8 Spec No.):E6. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk